PEGylation: An approach for drug delivery. A review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 25, Issue 5, 2008, Pages 403-447

  Jain, Aviral ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

PEG; PEGylation; Protein conjugates; RES uptake

Indexed keywords

ASPARAGINASE MACROGOL; HIRUDIN; MACROGOL; PEGADEMASE; PEGINTERFERON ALPHA2B; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALCATONIN;

CHEMICAL MODIFICATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INACTIVATION; DRUG STABILITY; DRUG STRUCTURE; GLOMERULUS FILTRATION; IMMUNOGENICITY; REVIEW; SINGLE DRUG DOSE;

EID: 52749092565     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v25.i5.10     Document Type: Review

References (187)

1. Shaffer CB, Critchfield FH. The absorption and excretion of the solid polyethylene glycols (carbowax compounds). J Am Pharm Assoc Am Pharm Assoc. 1947;36:152-7.
2. Smyth HF, Carpenter CP, Shaffer CB. The toxicity of high molecular weight poly ethylene glycols: chronic oral and parenteral administration. J Am Pharm Assoc. 1947;37:157-60.
3. Carpenter CP, Shaffer CB. A study of the poly ethylene glycols as vehicles for intramuscular and subcutaneous injections. J Am Pharm Assoc Am Pharm Assoc. 1952;41:27-9.
4. Smyth HF, Carpenter CB, Weil CS. The toxicology of the poly ethylene glycols. J Am Pharm Assoc. 1950;39:349-54.
5. Lee WY, Sehon AH, Akerblom E. Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. Int Arch Allergy Appl Immunol. 1981;64:100-14.
6. Tomiya N, Watanabe K, Awaya J, Kurono M, Fujii S. Modification of acylplasmin-streptokinase complex with polyethylene glycol. Reduction of sensitivity to neutralizing antibody. FEBS Lett. 1985;193:44-8.
7. Abuchowski A, Davis FF. Preparation and properties of polyethylene glycol-trypsin adducts. Biochem Biophys Acta. 1979;578:41-6.
8. Ashihara Y, Kono T, Yamazaki S, Inada Y. Modification of E. coli asparaginase with poly ethylene glycol: disappearance of binding ability to anti-asparaginase serum. Biochem Biophys Res Commun. 1978;83:385-91.
9. Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol accompanied with non-immunoreactivity towards anti-uricase serum and high enzymatic activity. Enzyme. 1981;26:49-53.
10. Nishimura H, Takahashi K, Sakurai K, Fujinuma K, Imamura Y, Ooba M, Inada Y. Modification of batroxobin with activated polyethylene glycol: reduction of binding ability towards anti-batroxobin antibody and retention of defibrinogenation activity in circulation of preimmunized dogs. Life Sci. 1985;33:1467-73.
11. Koide A, Kobayashi S. Modification of amino groups in procine pancreatic elastase with polyethylene glycol in relation to binding ability towards anti-serum and to enzymic activity. Biochem Biophys Res Commun. 1983;111:659-67.
12. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol) modified proteins. Adv Drug Deliv Rev. 1991;6:133-51.
13. Greenwald RB. PEG drugs: an overview. J Control Release. 2001;74:59-171.
14. Abuchowski A, Van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of poly ethylene glycol. J Biol Chem. 1977;11:3578-81.
15. Abuchowski A, Kazo G, Verhoest CR, Van Es T, Kafkewitz D, Nucci ML, Viau AT, Davis FF. Cancer therapy with chemically modified enzymes. I. Antitumor properties of poly ethylene glycol-modified asparaginase conjugates. Cancer Biochem Biophys. 1984;7:175-86.
16. Zalipsky S, Seltzer R, Nho K. Succinimidyl carbonates of poly ethylene glycol: useful reactive polymers for preparation of protein conjugates. In: Dunn RL, Ottenbrite RM, editors. Polymeric drugs and drug delivery systems. Washington (DC): American Chemical Society; 1991.
17. Beauchamp CO, Gonias SL, Menapace DP, Pizzo SV. A new procedure for the synthesis of poly ethylene glycol-protein adducts: effects on function, receptor recognition, and clearance of superoxidase dismutase, lactoferrin and α2-macroglobulin. Anal Biochem. 1983;131:25-33.
18. Ashihara Y, Kono T, Yamazaki S, Inada Y. Modification of E. coli asparaginase with poly ethylene glycol: disappearance of binding ability to anti-asparaginase serum. Biochem Biophys Res Commun. 1978;83:385-91.
19. Wieder KJ, Palczuk NC, Van Es T, Davis FF. Some properties of poly ethylene glycol: phenylalanine ammonia lyase adducts. J Biol Chem. 1979;254:12579-87.
20. Norman PS, King TP, Alexander JF, Kagey-Sobotka A, Lichtenstein LM. Immunologic responses to conjugates of antigen E in patients with ragweed hay fever. J Allergy Clin Immunol. 1984;73:782-9.
21. Wie SI, Wie CW, Lee WY, Filion LG, Sehon AH, Akerblom E. Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerance conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method. Int Arch Allergy Appl Immunol. 1981;64:84-99.
22. Lisi PJ, Van Es T, Abuchowski A, Palczuk NC, Davis FF. Enzyme therapy. I. Polyethylene glycol: B-glucuronidase conjugates as potential therapeutic agents in acid mucopolysaccharidosis. J Appl Biochem. 1982;4:19-33.
23. Sharp KA, Yalpani M, Howard SJ, Brooks DE. Synthesis and application of a poly(ethylene glycol)-antibody affinity ligand for cell separations in aqueous polymer two-phase systems. Anal Biochem. 1986;154:110-7.
24. Davis S, Abuchowski A, Park YK, Davis FF. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of poly ethylene glycol. Clin Exp Immunol. 1981;46:649-52.
25. Yoshinaga K, Harris JM. Circular dichromism and fluorescence of poly ethylene glycol modified alkaline phosphatase. J Bioact Compat Polym. 1989;4:17-24.
26. Pasta P, Riva S, Carrea G. Circular dichroism and fluorescence of polyethylene glycol-subtilisin in organic solvents. FEBS Lett. 1988;236:329-32.
27. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, Abuchowski A. Treatment of adenosine deaminase deficiency with poly ethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589-96.
28. Hadley KB, Sato PH. Catalytic activity of administered gulonolactone oxidase poly ethylene glycol conjugates. Enzyme. 1989;42:225-34.
29. Dreborg S, Akerblom EB. Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst. 1990;6:315-65.
30. Ulbrich K, Strohalm J, Kopecek J. Polyethylene glycols containing enzymatically degradable bonds. Makromol Chem. 1986;187:1131-44.
31. Stenlake JB. Foundations of molecular pharmacology: the chemical basis of drug action. Vol. II. London (UK): The Athlone Press; 1979. p. 213.
32. Beauchamp CO, Daddona PE, Menapace DP. Properties of novel PEG derivative of calf adenosine deaminase. Adv Exp Med Biol. 1984;165:47-52.
33. Berger H, Pizzo SV. Preparation of polyethylene glycol tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. Blood. 1988;71:1641-7.
34. Hooftman G, Herman S, Schacht E. Polyethylene glycols with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polymers. 1996;11:135-59.
35. Vandegriff KD, McCarthy M, Rohlfs RJ, Winslow RM. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys Chem. 1997;69:23-30.
36. Harris JM, editor. Poly (ethylene glycol) chemistry: biotechnical and biomedical applications. New York: Plenum Publishing; 1992.
37. Toy PH, Janda KD. Soluble polymer-supported organic synthesis. Acc Chem Res. 2000;33:546-54.
38. Zalipsky S, Gilon C, Zilkha A. Attachment of drugs to polyethylene glycols. Eur Polym J. 1983;19:1177-83.
39. Herman S, Hooftman G, Schacht E. Poly (ethylene glycol) with reactive end groups: I. Modification of proteins. J Bioact Compat Polym. 1995;10:145-87.
40. Zalipsky S. Functionalized poly (ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem. 1995;6:150-65.
41. Greenwald RB, Pendri A, Bolikal D. Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J Org Chem. 1995;60:331-6.
42. Pendri A, Gilbert CW, Soundararajan S, Bolikal D, Shorr RGL, Greenwald RB. PEG modified anticancer drugs: synthesis and biological activity. J Bioact Compat Polym. 1996;11:122-34.
43. Abuchowski A, McCoy TJR, Palczuk NC, Van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252:3582-6.
44. Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol. 1998;35:291-8.
45. Ho PPK, Milkin EB, Bobbitt JL, Grinnan EL, Burck PJ, Frnak BH, Boeck LVD, Squires RW. Crystalline L-asparaginase from Escherichia coli B. J Biol Chem. 1970;245:3706-15.
46. Wang Y, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of PEGylated IFN alpha-2b. Biochemistry. 2000;39:10634-40.
47. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens S. Structural and biologic characterization of PEGylated recombinant IFN-α-2b. J. IFN Cytokine Res. 2001;21:1103-15.
48. Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, Cutler C, Pramanik B. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm Res. 2001;18:1354-60.
49. Morstyn G, Foote M, Walker T, Molineux G. Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol. 2001;105:151-5.
50. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-31.
51. Yang JC, Topalian SL, Parkinson DR, Marincola FM. The use of polyethylene glycol modified interleukin-2 (PEG-II-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 1995;76:687-94.
52. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-7.
53. Lustig R, Byhardt R, Diab S, Lillis P, Vigneri P, Kwiatek J, Viau AT. A clinical phase IB study of PEG-hemoglobin in patients receiving palliative fractionated radiation for solid tumors [abstract]. J Clin Oncol. 1999;17:1750.
54. Collen D, Sinnaeve P, Demarsin E, Moreau H, De Maeyer M, Jespers L, Laroche Y, Van de Werf F. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation. 2000;102:1766-72.
55. Greenwald RB, Choe YHM. McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003;55:217-50.
56. Esslinger HU, Hass S, Maurer R, Lassman A, Dubbers K, Muller-Peltzer H. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Thromb Haemost. 1997;77:911-7.
57. Yoo SD, Jun H, Shin BS, Lee HS, Park MO, Deluca PD, Lee KC. Pharmacokinetic disposition of polyethylene glycol modified salmon calcitonins in rats. Chem Pharm Bull. 2000;48:1921-4.
58. Jaschke A, Furste JP, Cech D, Erdmann VA. Automated incorporation of polyethylene glycol into synthetic oligonucleotides. Tetrahedron Lett. 1993;34:301-4.
59. Seelig B, Jäschke A. Site-specific modification of enzymatically synthesized RNA: Transcription initiation and Diels-Alder reaction. Tetrahedron Lett. 1997;38:7729-32.
60. Kawaguchi T, Asakawa H, Tashiro Y, Juni K, Sueishi T. Stability, specific binding activity and plasma concentration in mice of an oligodeoxynucleotide modified at 5′ terminal with poly(ethylene glycol). Biol Pharm Bull. 1995;18:474-6.
61. Bonora GM, Ivanova E, Zarytova V, Burcovich B, Veronese FM. Synthesis and characterization of high-molecular mass polyethylene glycolconjugated oligonucleotides. Bioconjug Chem. 1997;8:793-7.
62. Jaschke A, Furste JP, Nordhoff E, Hillenkamp F, Cech D, Erdmann VA. Synthesis and properties of oligodeoxyribonucleotides-polyethylene glycol conjugates. Nucleic Acids Res. 1994;22:4810-7.
63. Burcovich B, Veronese FM, Zarytova V, Bonora GM. Branched polyethylene glycol (bPEG) conjugated antisense oligonucleotides. Nucleos Nucleot. 1998;17:1567-70.
64. Vorobjev PE, Zarytova VF, Bonora GM. Oilgonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNAse H. Nucleos Nucleot. 1999;18:2745-50.
65. Rapozzi V, Cogoi S, Spessotto P, Risso A, Bonora GM, Quadrifoglio F, Xodo LE. Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcrlabl oncogene. Biochemistry. 2002;41:502-10.
66. Lee LS, Conover C, Shi C, Whitlow M, Filpula D. Prolonged circulation lives of single-chain Fv protein conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjugate Chem. 1999;10:973-81.
67. 2 by amine-specific PEGylation with preserved bioactivity. Int J Pharmaceut. 2000;198:83-95.
68. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol) modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem. 2000;11:258-66.
69. Matthew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem. 1992;35:145-57.
70. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 1991;6:181-202.
71. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem. 1992;3:351-62.
72. Noguchi Y, Wun J, Duncan R, Strohalm R, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res. 1998;89:307-14.
73. Greenwald RB, Pendri A, Bolikal D, Gilbert CW. Highly water soluble taxol derivatives: 2-polyethylene glycol esters as potential prodrugs. Bioorg Med Chem Lett. 1994;4:2465-70.
74. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83:601-6.
75. Stella VJ, Charman WNA, Naringrekar VH. Prodrugs: do they have advantages in clinical practice? Drugs. 1985;29:455-73.
76. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A. Drug delivery systems: water soluble taxol 2-poly (ethylene glycol) ester prodrugs - design and in vivo effectiveness. J Med Chem. 1996;39:424-31.
77. Carl PL, Chakravarty PK, Katzenellenbogen JA. A novel connector linkage applicable in prodrug design. J Med Chem. 1981;24:479-80.
78. Bundgaard H. The double prodrug concept and its applications. Adv Drug Deliv Rev. 1989;3:39-65.
79. Pendri A, Conover CD, Greenwald RB. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water soluble prodrug. Anticancer Drug Design. 1998;13:387-95.
80. Greenwald RB, Pendri A, Conover CD, Lee C, Choe YH, Gilbert C, Martinez A, Xia J, Wu D, Hsue M. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg Med Chem. 1998;6:551-62.
81. Yokoyama M, Okana T. Targetable drug carriers: present status and a future perspective. Adv Drug Deliv Rev. 1996;21:77-80.
82. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethylene glycol) protein conjugates. Adv Drug Del Rev. 2003;55:1261-77.
83. Harris JH, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2000;40:539-51.
84. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992;9:249-304.
85. Monfardini C, Veronese FM. Stabilization of substances in circulation. Bioconjug Chem. 1998;9:418-50.
86. Jensen-Pippo KE, Whitcomb KL, DePrince RB, Ralph L, Habberfield AD. Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharm Res. 1996;13:102-7.
87. Yamaoka T, Tabata Y, Ikada Y. Fate of water soluble polymers administered via different routes. J Pharm Sci. 1995;84:349-54.
88. Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous injection. J Pharm Pharmacol. 1995;47:479-86.
89. Yabe Y, Nishikawa M, Tamada A, Takakura Y, Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxidase dismutase. J Pharmacol Exp Ther. 1999;289:1176-84.
90. Kartre K. The conjugation of proteins with poly(ethylene glycol) and other polymers. Adv Drug Deliv Rev. 1993;10:91-110.
91. Rabkin R, Dahl DC. Renal uptake and disposal of proteins and peptides. In: Audus KL, Raub TJ, editors. Biological barriers in protein delivery. New York: Plenum Press; 1993. p. 299.
92. Brenner BN, Hostetter TH, Humes HD. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am J Physiol. 1978;234:F455-60.
93. Deen WM, Bohrer MP, Brenner BN. Macromolecule transport across glomerular capillaries: application of pore theory. Kidney Int. 1979;16:353-65.
94. Kompella UB, Lee VHL. Pharmacokinetics of peptide and protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker; 1991. p. 391.
95. Saifer MGP, Williams LD, Sherman MR, French JA, Kwak LW, Oppenheim JJ. Improved conjugation of cytokines using high molecular weight poly (ethylene glycol): PEG-GM-CSF as prototype. Polym Preprints. 1997;38:576-7.
96. Caliceti P, Schiavon O, Veronese FM. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjug Chem. 1999;10:638-46.
97. Lamka J, Schiavon O, Laznicek M, Caliceti P, Veronese FM. Distribution of catalase, ribonuclease, superoxidase dismutase modified by monomethoxy (polyethylene glycol) into rat cerebral lymph and lymphatic nodes. Physiol Res. 1995;44:307-13.
98. Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, Braeckman RA. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther. 2000;293:248-59.
99. Xie D, Hale VG. Factors affecting the lymphatic absorption of macromolecules following extravascular administration. Pharm Res. 1996;13:S-396.
100. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22:405-17.
101. Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition of macromolecules in tumor bearing mice. Pharm Res. 1990;7:339-46.
102. Knauff MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Kartre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers. J Biol Chem. 1988;263:15064-70.
103. Nakaoda R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly (ethylene glycol) modification. J Control Release. 1997;46:253-62.
104. Sherman MR, Williams LD, Saifer MCP, French JA, Kwak LW, Oppenheim JJ. Conjugation of high molecular weight poly (ethylene glycol) to cytokines: granulocyte-macrophage colony stimulating factors as model substrates. In: Harris JM, Zalipsky S, editors. Poly(ethylene glycol): chemistry and biological applications. Washington (DC): American Chemical Society; 1997. p. 155-69.
105. Arendshorst WJ, Navar LG. Renal circulation and glomerular hemodynamics. In: Schrier RW, Gottshalk CW, editors. Diseases of the kidney. Boston (MA): Little, Brown; 1988. p. 65.
106. Conover CD, Gilbert CW, Shum KL, Shorr RL. The impact of polyethylene glycol conjugation on bovine hemoglobin's circulating half-life and renal effects in a rabbit top-loaded transfusion model. Artif Organs. 1997;21:907-15.
107. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 1999;17:780-3.
108. Renkin EM, Gilmore JP. Glomerular filtration. In: Orloff J, Berliner RW, editors. Handbook of physiology - renal physiology. Bethesda (MD): American Physiological Society; 1973. p. 185-248.
109. Poste G. Liposome targeting in vivo: problems and opportunities. Biol Cell. 1983;47:19-38.
110. Kataoka K. Targetable polymeric drugs. In: Park K, editor. Controlled drug delivery challenges and strategies. Washington (DC): American Chemical Society; 1997. p. 49.
111. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur J Cancer. 1995;31:766-70.
112. Sawa T, Wu J, Akaike T, Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 2000;60:666-71.
113. Edwards CK. PEGylated recombinant human soluble tumor necrosis factor receptor type I (r-Hu-sTNF-RI) novel high affinity TNF receptor designed for chronic inflammatory disease. Ann Rheum Dis. 1999;58:173-81.
114. Sehon AH. Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol). Adv Drug Deliv Rev. 1991;6:203-17.
115. Caliceti P, Veronese FM, Jonak Z. Immunogenic and tolerogenic properties of monomethoxypoly (ethylene glycol) conjugated drugs. Farmaco. 1999;54:430-7.
116. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 1983;70:124-31.
117. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74:36-9.
118. Tsuji JC, Hirose K. Studies on antigenicity of polyethylene glycol (PEG)-modified uricase. Int J Immunopharmacol. 1985;7:725-30.
119. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. Pegylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. Int J Hematol. 1998;68:1-18.
120. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531-45.
121. Veronese FM, Manfardini C, Calictei P, Schiavon O, Scrawen MD, Beer D. Improvement of pharmacokinetic, immunological and stability properties of asparginase by conjugation of linear and branched mono methoxy poly(ethylene glycol). J Control Release. 1966;40:199-209.
122. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem. 1999;10:520-8.
123. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to L-asparaginase derived from E. coli and Erwinia cultures. Cancer. 1976;38:1843-6.
124. Fabry U, Koerholz D, Jurgens H, Goebel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement mediated mechanism. Pediatr Res. 1985;19:400-8.
125. Testa B, Mayer JM. Design of intramolecularly activated prodrugs. Drug Metab Rev. 1998;30:787-807.
126. Wahn V, Fabry U, Koerholz D, Reinhardt D, Jurgens H, Goebel U. Modified pharmacokinetics of L-asparaginase from E. coli by the formation of specific antibodies to L-asparaginase of different immunoglobulin classes in children with acute lymphoblastic leukemia. Pediatr Pharmacol. 1983;3:303-11.
127. Goldberg AI, Cooney DA, Glynn JP, Homan ER, Gaston MR, Milman HA. The effects of immunization to L-asparaginase on antitumor and enzymatic activity. Cancer Res. 1973;33:256-61.
128. Capizzi RL, Bertino JR, Handschumacher RE. L-asparaginase. Ann Rev Med. 1970;21:433-44.
129. Ho DH, Yap HY, Brown N, Blumenschein GR, Bodey GP. Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol. 1981;21:72-8.
130. Ho DH, Frei E. Clinical pharmacologic studies of L-asparaginase. Clin Pharmacol Ther. 1970;11:408-17.
131. Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970;30:2297-305.
132. Jürgens H, Schwamborn D, Körholz D, Wahn V, Göbel U. [Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia] [German]. Klin Padiatr. 1988;200(3):184-9.
133. MacEwen EG, Rosenthal R, Matus R, Viau AT, Abuchowski A. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine lymphosarcoma. Cancer. 1987;59:2011-5.
134. Teske E, Rutterman GR, Van Heerde P, Misdorp W. L-asparaginase in non-Hodgkin's lymphoma: a phase III trial in a canine model. Anticancer Res. 1988;8:1117S.
135. Muss HB, Spell N, Scudiery D, Capizzi RL, Cooper MR, Cruz J, Jackson DV, Richards F II, Spurr CL, White DR. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphoma. Invest New Drugs. 1990;8:125-30.
136. Savoca KV, Abuchowski A, Van Es T, Davis FF, Palczuk NC. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochem Biophys Acta. 1979;578:47-53.
137. Savoca KV, Davis FF, van Es T, McCoy JR, Palczuk NC. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase and arginase modified by the covalent attachment of polyethylene glycol, on the Taper liver tumor and the L5178Y murine leukemia. Cancer Biochem Biophys. 1984;7:261-8.
138. Abuchowski A, Davis FF, Davis S. Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man. Cancer Treat Rep. 1981;65:1077-81.
139. Fuertges F, Abuchowski A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J Control Release. 1990;11:139-48.
140. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Ekimoto H, Kataoka K. In vivo antitumor activity of polymeric micelle anticancer drug against murine C 26 tumor. J Control Release. 1994;28:336-7.
141. Hirschhorn R, Vawter GR, Kirkpatrick JA, Rosen FS. Adenosine deaminase deficiency: frequency and comparative pathology in autosomally recessive severe combined immunodeficiency. Clin Immunol Immunopathol. 1979;14:107-20.
142. Claassen JL, Kobayashi RH, Kobayashi AL, Hershfield MS, Schiff RI, Buckley RH. Antigen-specific humoral and cellular immune responses during treatment of adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) with polyethylene glycol-modified bovine adenosine deaminase (PEG-ADA). J Allergy Clin Immunol. 1988;81:237.
143. Kobayashi AD, Kobayashi RH, Schiff RI, Claassen J, Hershfield MS. The use of bovine polyethylene glycol-modified adenosine deaminase (PEGADA) in correcting the immunodeficiency in a child with severe combined immunodeficiency-adenosine deaminase deficiency (SCID-ADA [-]). J Allergy Clin Immunol. 1988;81:237.
144. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RK. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase. J Pediatr. 1988;113:312-7.
145. Mitsino T, Ohyanagi H, Yoyokama H. Development of perfluorochemical emulsion as blood gas carrier. Artif Organs. 1984;8:25-33.
146. Marwich C. FDA committee questions Flusol efficacy: US approval not imminent. JAMA. 1983;250:2585-6.
147. Tam SC, Blumenstein, Wong JTF. Soluble dextran-hemoglobin complex as a potential blood substitute. Proc Natl Acad Sci U S A. 1976;73:2128-31.
148. Cerny LC, Cerny EL, Roback J, Reath M, Pontero L. A blood substitute from hydroxyethyl starch and hemoglobin. Appl Biochem Biotechnol. 1984;10:151-3.
149. Fedorov NA, Yorochkin VS, Koxiner VB, Khachaturyan AA, Rozenberg GY. The maintenance of respiration and hemodynamics after complete replacement of blood with artificial oxygen transporters: polyhemoglobin-albumin and polyhemoglobin. Dokl Acad Nauk SSSR. 1978;243:1324-6.
150. Ajisaka K, Iwashita Y. Modification of human hemoglobin with polyethylene glycol: a new candidate for blood substitute. Biochem Biophys Res Commun. 1980;87:1076-81.
151. DeVenuto F, Zegna A. Preparation and evaluation of pyridoxylated- polymerized human hemoglobin. J Surg Res. 1983;34:205-12.
152. Moss GS, Gould SA, Sehgal LR, Sehgal HL, Rosen AL. Hemoglobin solution - from tetramer to polymer. Surgery. 1984;95:249-55.
153. Iwasaki K, Ajisaka K, Iwashita Y. Hemoglobin-insulin conjugate as an oxygen carrying blood substitute. Biochem Biophys Res Commun. 1983;113:513-8.
154. Friedman HI, DeVenuto F, Lollini L, Mellick P, Zuch TF. Morphologic effects following massive exchange transfusions with a stroma-free hemoglobin solution I. Liver. Lab Invest. 1978;39:167-77.
155. Iwasaki K, Iwashita Y. Preparation and evaluation of hemoglobinpolyethylene glycol conjugate (pyridoxylated polyethylene glycol hemoglobin) as an oxygen carrying resuscitation fluid. Artif Organs. 1986;10:411-6.
156. Leonard M, Neel J, Dellacherie E. Synthesis of monomethoxy polyethylene-bound hemoglobins. Tetrahedron. 1984;40:1581-4.
157. Leonard M, Dellacherie E. Acylation of human hemoglobin with polyethylene derivative. Biochem Biophys Acta. 1984;791:219-25.
158. Matsushita M, Iwashita Y, Iwasaki K, Ohki H, Nasu M, Horiuchi T, Chen JF, Goldcamp J, Murabayashi S, Harasaki H, Malcheski PS, Nose Y. Physiologic effects of pyridoxylated-hemoglobin-polyethylene glycol conjugate solution in exchange transfusions. Trans Am Soc Artif Intern Organs. 1986;32:490-4.
159. Menu P, Pauly F, Labrude P, Vigneron C. Haemoglobin pyridoxylation: optimization and observation of an additional new pyridoxal-haemoglobin species by high-performance liquid chromatographic resolution. J Chromatogr. 1987;417:397-402.
160. Nishi K, Yamakawa T, Ohta T. Transfusion of polyoxyethylene conjugate of pyridoxylated human hemoglobin in dogs with hemorrhagic shock. Biomater Artif Cells Artif Organs. 1987;15:381.
161. Procter PH, Reynolds ES. Free radicals and disease in man. Physiol Chem Phys Med NMR. 1984;16:175-95.
162. Crapo JD, Tierney DF. Superoxide dismutase and pulmonary toxicity. Am J Physiol. 1974;226:1401-7.
163. Mossman BT, Marsh JP, Hardwick D, Gilbert R, Hill S, Sesko A, Shatis M, Doherty J, Weller A, Bergeron M. Approaches to prevention of asbestos-induced lung diseases using polyethylene glycol (PEG)-conjugated catalase. J Free Rad Biol Med. 1986;2:335-8.
164. Granger DN, Rutili G, McCord J. Superoxide radicals in feline intestinal ischemia. Gastroenterology. 1981;81:22-9.
165. McCord JM. Oxygen derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-63.
166. Huber W, Menander-Huber H. Orgotein. Clin Rheum Dis. 1980;6:465-9.
167. Lund-Oleson K, Menander KB. Orgotein: a new anti-inflammatory metalloprotein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease. Curr Ther Res Clin Exp. 1974;16:706-17.
168. Marberger H, Bertesch G, Huber W, Menander K, Schulte T. Orgotein: a new drug for the treatment of radiation cystitis. Curr Ther Res. 1975;18:466-75.
169. Rosenfeld W, Evans H, Jhaveri R, Moainie H, Vohra K, Georgatos E, Salazar JD. Safety and plasma concentrations of bovine superoxide dismutase administered to human premature infants. Dev Pharmacol Ther. 1982;5:151-61.
170. Izakovic V, Strbakova E, Kaiserova E, Krizan P. Bovine superoxidase dismutase in Fanconi anemia: therapeutic trial in two patients. Hum Genet. 1985;70:181-2.
171. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms: the production by leukocytes of superoxidase dismutase, a potent bactericidal agent. J Clin Invest. 1973;52:741-4.
172. Huber W, Saifer MGP. Orgotein: the drug version of bovine Cu, Zn superoxide dismutase: I. A summary account of safety and pharmacology in laboratory animals. In: Michelson AM, McCord JM, Fridovich I, editors. Superoxide and superoxide dismutase. New York: Academic Press; 1977. p. 517-36.
173. Turrens JT, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest. 1984;73:87-95.
174. Beckman JS, Minor RL, White CW, Repine JE, Rosen GM, Freeman BA. Superoxidase dismutase and catalase conjugated to polyethylene glycol increase endothelial enzyme activity and oxidant resistance. J Biol Chem. 1988;236:6884-92.
175. White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, Berger EM, Freeman BA, McCord JM, Repine JE. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J Appl Physiol. 1989;66:584-90.
176. Bennett J, Bry WI, Collins GM, Halasz NA. The effect of oxygen free radicals on the preserved kidney. Cryobiology. 1987;24:264-9.
177. Mayhew EG, Lasic D, Babbar S, Martin FJ. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol derivatized phospholipid. Int J Cancer. 1992;51:302-9.
178. Inada Y, Matsushima A, Kodera Y, Nishimura H. Polyethylene glycol (PEG) protein conjugates: application to biomedical and biotechnological processes. J Bioact Compat Polym. 1990;5:343-64.
179. Inada Y, Nishimura H, Takahashi K, Yoshimoto T, Saha AR, Saito Y. Ester synthesis catalysed by polyethylene glycol-modified lipase in benzene. Biochem Biophys Res Commun. 1984;122:845-50.
180. Ajima A, Yoshimoto T, Takahashi K, Tamaura Y, Saito Y, Inada Y. Polymerization of 10-hyroxydecanoic acid in benzene with polyethylene glycol lipase. Biotechnol Lett. 1985;7:303-6.
181. Wirth P, Souppe J, Tritsch D, Biellmann JF. Chemical modification of horseradish peroxidase with ethanol-methoxypolyethylene glycol: solubility in organic solvents, activity and properties. Bioorg Chem. 1991;19:133-42.
182. Illum L, Davis SS. Targeting of colloidal particles to the bone marrow. Life Sci. 1987;40:1553-60.
183. Porter CJ, Moghimi SM, Illum L, Davis SS. The poloxamer-407 selectivity redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 1992;305:62-6.
184. Katre NV, Knauf MJ. Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation. United States patent US 4,917,888. 1990 Apr 17.
185. Yokoyama M, Inoue S. Molecular design for missile drug: synthesis of adriamycin conjugated with immunoglobulin G using polyethylene glycol-block-polyaspartic acid as intermediate carrier. Makromol Chem. 1989;190:2041-54.
186. Allen HJ, Sharma A, Matta AK. Synthesis and carbohydrate-binding activity of polyethylene glycol-Ricinus communis agglutinin I conjugates. Carbohydr Res. 1991;213:309-19.
187. Kundsen GR, Eschen DJ, Dandurand LM, Wang ZG. Method to enhance growth and sporulation of pelletized biocontrol fungi. Appl Environ Microbiol. 1991;57:2864-7.